Phaseline

Companies › Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing)

Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing): clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Genitourinary, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RG002C0106
siRNA targeting complement C3 to silence the gene and inhibit C3 protein expression
C3Phase 2IgA Nephropathy (IgAN); Safety Issues; Renal ImpairmentsDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06494527RG002C0106Phase 1Safety IssuesOtherAug 2026
NCT07445906RG002C0106Phase 1Renal ImpairmentsGenitourinaryDec 2026
NCT07305974RG002C0106Phase 2IgA Nephropathy (IgAN)GenitourinaryMar 2029

Targets

C3 (1)

Companies with the same targets

Apellis Pharmaceuticals Annexon Kodiak Sciences Shenyang Sunshine Pharmaceutical Swedish Orphan Biovitrum

Companies built like this

Apellis Pharmaceuticals Shanghai Bao Pharmaceuticals Akebia Therapeutics Healx Skingenix

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.